Analyst Rating Update on Becton Dickinson and Company (BDX)

Becton Dickinson and Company (NYSE:BDX) : Zacks Investment Research ranks Becton Dickinson and Company (NYSE:BDX) as 3, which is a Hold recommendation. 9 research analysts consider that the stocks fundamentals point to a bright future, hence they rate the stock as a Strong Buy. A total of 5 analysts believe that the stock has a limited upside, hence they advise a Hold. The average broker rating of 14 research analysts is 1.71, which indicates as a Buy.

Becton Dickinson and Company (NYSE:BDX) : The consensus price target for Becton Dickinson and Company (NYSE:BDX) is $179.55 for the short term with a standard deviation of $6.79. The most optimist securities analyst among the 11 who monitor the stock believes that the stock can reach $190, however, the pessimist price target for the company is $169.

For the current week, the company shares have a recommendation consensus of Buy.

Becton Dickinson and Company (NYSE:BDX): stock turned positive on Tuesday. Though the stock opened at $163.98, the bulls momentum made the stock top out at $164.68 level for the day. The stock recorded a low of $162.88 and closed the trading day at $164.08, in the green by 0.66%. The total traded volume for the day was 1,400,435. The stock had closed at $163.01 in the previous days trading.

In an insider trading activity,The officer (VP, Corp Finance and Treasurer) of Becton Dickinson & Co, Gallagher John E sold 1,931 shares at $169.87 on June 13, 2016. The Insider selling transaction had a total value worth of $328,019. The Insider information was disclosed with the Securities and Exchange Commission in a Form 4 filing.

Becton, Dickinson and Company is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products used by healthcare institutions, life science researchers, clinical laboratories, pharmaceutical industry and the general public. The Company operates through two segments: BD Medical and BD Life Sciences. The Companys Life Sciences segment consists of the BD Diagnostics and BD Biosciences segments. The Companys BD Medical segment focuses on providing solutions to reduce the spread of infection, enhance diabetes treatment and advance drug delivery. The Companys BD Diagnostics provides products for the safe collection and transport of diagnostics specimens, as well as instruments and reagent systems. Its BD Biosciences provide diagnostic and research tools to life science researchers, clinical researchers, laboratory professionals and clinicians.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.